0.0000 (0.0000%)
  • Bid / Lots
    2.0200/ 1
  • Ask / Lots
    4.3600/ 4
  • Open / Previous Close
    3.7500 / 3.7050
  • Day Range
    Low 3.6000
    High 3.8744
  • 52 Week Range
    Low 1.6600
    High 5.8300
  • Volume
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 3.87
09:32 ET12863.75
09:45 ET23003.84
09:50 ET10003.82
09:54 ET3003.815
09:56 ET3003.84
10:08 ET10003.87
10:15 ET12003.87
10:19 ET1003.87
10:24 ET1823.815
10:30 ET3993.755
10:35 ET2003.755
10:44 ET107993.75
10:46 ET6273.7483
10:48 ET38703.72
10:55 ET3343.72
11:06 ET1003.66
11:09 ET8003.65
11:11 ET2763.75
11:13 ET2003.74
11:18 ET6003.75
11:22 ET8273.6525
11:27 ET4003.75
11:29 ET6003.72
11:40 ET48003.72
11:58 ET1003.65
01:26 ET10003.7
01:28 ET13333.7078
01:35 ET190003.705
01:50 ET3143.69
01:51 ET1003.68
01:53 ET5203.7
02:11 ET1003.715
02:51 ET15003.68
03:21 ET1003.69
03:25 ET6503.67
03:30 ET31943.6
03:32 ET47893.6066
03:34 ET1003.64
03:36 ET3003.66
03:38 ET2003.69
03:59 ET34893.705
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPRLD
Prelude Therapeutics Inc
United StatesELYM
Eliem Therapeutics Inc
United StatesRENB
Renovaro Inc
United StatesATAI
ATAI Life Sciences NV
United StatesZURA
Zura Bio Ltd
United StatesGLUE
Monte Rosa Therapeutics Inc
As of 2024-06-21

Company Information

Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.

Contact Information

175 Innovation BoulevardWILMINGTON, DE, United States 19805


Independent Chairman of the Board
Paul Friedman
President, Chief Medical Officer
Jane Huang
Chief Executive Officer, Founder, Director
Krishna Vaddi
Interim Chief Financial Officer, Chief Legal Officer, Corporate Secretary
Bryant Lim
Senior Vice President of Investor Relations
Robert Doody

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.